...
首页> 外文期刊>Ukrainian Biochemical Journal >Preparation of highly-concentrated autologous platelet-rich plasma for biomedical use
【24h】

Preparation of highly-concentrated autologous platelet-rich plasma for biomedical use

机译:高浓度自体富血小板生物医学血浆的制备

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Cell therapy with platelets is a widely accepted approach for wound healing and tissue regeneration in medicine. However, with most available methods poorly concentrated platelet suspensions (up to 0.3?10sup6/sup?1/μl) or suspensions of mostly inactivated or lost platelets are obtained. In this study, we aimed to develop a simple and effective method for preparing a suspension of native and resting platelets with over 1?10sup6/sup 1/μl. Platelet-rich plasma (PRP) was obtained from fresh blood of healthy donors ( n = 5) collected using different amounts of heparin as the anticoagulant. Samples of PRP were spun down and re-suspended in autologous blood plasma. Count and vitality of platelets in each sample were determined by aggregation study on the Solar AP2110 aggregometer. Platelet shape and cytoplasmic granularity that indicate the nativity of platelets were monitored on the COULTER EPICS XL Flow Cytometer. This study of aggregation of platelets in PRP obtained using various amounts of heparin allowed us to reduce final concentrations to the amount that effectively prevented clotting and did not affect platelet reactivity (5 U/ml). PRP concentrated 5 times with a total concentration of cells of 1?10sup6/sup 1/μl was able to be activated by adenosine diphosphate (ADP) (aggregation rate 54 ± 7%). The amount of cells with altered shape and granularity in concentrated suspension was not higher than 20%. This finding means that the platelets would still be able to release a number of growth factors and other biologically active compounds after stimulation or injection into tissue during cell therapy. The decrease in heparin concentrations also minimizes haemorrhage in the injection site supporting biomedical use of the suspension. A simple and effective method for preparation of highly-concentrated PRP (1.2?106 1/μl) for biomedical use was developed. Aggregometry and flow cytometry proved that obtained platelets were resting and able to be activated. Being autologous, the preparation can be widely used for cell therapy without additional precautions.
机译:用血小板进行细胞疗法是医学上用于伤口愈合和组织再生的广泛接受的方法。但是,使用大多数可用方法,可获得的血小板悬浮液浓缩不良(最高0.3?10 6 ?1 /μl)或大部分失活或丢失的血小板悬浮液。在这项研究中,我们旨在开发一种简单有效的方法来制备天然血小板和静息血小板的悬浮液,其悬浮液的浓度应超过1?10 6 1 /μl。使用不同量的肝素作为抗凝剂,从健康供体(n = 5)的新鲜血液中获取富含血小板的血浆(PRP)。将PRP样品离心分离并重悬于自体血浆中。通过在Solar AP2110凝集仪上进行聚集研究确定每个样品中血小板的数量和活力。在COULTER EPICS XL流式细胞仪上监测表明血小板诞生的血小板形状和细胞质粒度。这项使用各种量的肝素获得的PRP中血小板聚集的研究使我们可以将最终浓度降低至有效防止凝结且不影响血小板反应性的量(5 U / ml)。 PRP浓缩5次,细胞总浓度为1?10 6 1 /μl,可以被二磷酸腺苷(ADP)激活(聚集率54±7%)。浓缩悬液中形状和粒度改变的细胞数量不高于20%。这一发现意味着血小板在细胞治疗期间被刺激或注射入组织后仍将能够释放多种生长因子和其他生物活性化合物。肝素浓度的降低也使注射部位的出血最小化,从而支持悬浮液的生物医学用途。开发了一种简单有效的方法来制备生物医学用高浓度PRP(1.2?106 1 /μl)。凝集测定法和流式细胞术证明所获得的血小板处于静止状态并能够被激活。由于是自体的,因此该制剂无需其他预防措施即可广泛用于细胞治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号